Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis
AH Tavenier, R Mehran, M Chiarito… - European Heart …, 2022 - academic.oup.com
Aim Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary
intervention (PCI) for acute coronary syndrome (ACS) intends to balance ischemic and …
intervention (PCI) for acute coronary syndrome (ACS) intends to balance ischemic and …
De-escalation from prasugrel or ticagrelor to clopidogrel in patients with acute coronary syndrome managed with percutaneous coronary intervention: an updated …
Introduction We aimed to evaluate the clinical benefits of a de-escalation strategy from
prasugrel or ticagrelor to clopidogrel versus continuation of prasugrel or ticagrelor along …
prasugrel or ticagrelor to clopidogrel versus continuation of prasugrel or ticagrelor along …
[HTML][HTML] Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL
O Kourti, O Konstantas, IΤ Farmakis… - Reviews in …, 2022 - imrpress.com
Background: Superiority of potent P2Y12 inhibitors over clopidogrel after an acute coronary
syndrome (ACS) has been well established, however potent P2Y12 inhibition is responsible …
syndrome (ACS) has been well established, however potent P2Y12 inhibition is responsible …
A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo …
The risk of ischemic events gradually decreases after acute coronary syndrome (ACS),
reaching a stable level after 1 month, while the risk of bleeding remains steady during the …
reaching a stable level after 1 month, while the risk of bleeding remains steady during the …
Efficacy and safety of different dual antiplatelet strategies in patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis
Y Wongsalap, K Kengkla, P Wilairat… - Chronic Diseases and …, 2023 - mednexus.org
Background: Dual antiplatelet therapy (DAPT) is key for preventing ischaemic events post-
percutaneous coronary intervention (PCI). Various DAPT modifications like the shortened …
percutaneous coronary intervention (PCI). Various DAPT modifications like the shortened …
Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome—a systematic review and meta-analysis
N Bergh, A Myredal, P Nivedahl… - Journal of …, 2022 - journals.lww.com
The efficacy and safety of clopidogrel compared with ticagrelor as part of dual antiplatelet
therapy in patients, and in older patients, with acute coronary syndrome is reviewed …
therapy in patients, and in older patients, with acute coronary syndrome is reviewed …
[HTML][HTML] Potent P2Y12 Inhibitor Selection and De-Escalation Strategies in Acute Coronary Syndrome Patients Undergoing PCI: Systematic Review and Meta-analysis
LA Boivin-Proulx, KR Bainey, G Marquis-Gravel… - CJC open, 2023 - Elsevier
Background Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent
P2Y 12 inhibitors remains a challenge in the management of acute coronary syndrome …
P2Y 12 inhibitors remains a challenge in the management of acute coronary syndrome …
Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of …
N Bai, Y Ma, Y Niu, PY Zhong, YS Shang… - Journal of …, 2022 - journals.lww.com
Considering that there is no definite conclusion on the efficacy and safety of switching from
potent P2Y 12 inhibitors to clopidogrel, we conducted a systematic review and meta …
potent P2Y 12 inhibitors to clopidogrel, we conducted a systematic review and meta …
De-escalating dual antiplatelet therapy in patients with acute coronary syndromes: the right strategy to harmonize time-dependent ischemic and bleeding risk in …
G Crimi, R De Rosa, A Mandurino-Mirizzi… - Journal of …, 2020 - journals.lww.com
Abstract The European Society of Cardiology guidelines for myocardial revascularization
state that de-escalation of P2Y12 inhibitor treatment guided by platelet function testing may …
state that de-escalation of P2Y12 inhibitor treatment guided by platelet function testing may …
The Coagulology Section of the Polish Society of Laboratory Diagnostics recommendations on the platelet reactivity test. 2023
J Golański, A Raszeja-Specht - Journal of …, 2023 - diagnostykalaboratoryjna.eu
Platelet reactivity testing is used for a wide variety of clinical purposes; firstly, to study
platelet dysfunction in acute bleeding and diagnosis of platelet disorders in patients with …
platelet dysfunction in acute bleeding and diagnosis of platelet disorders in patients with …